News

Home / News
Launch of a Generic Version of Pyridostigmine Bromide Syrup

Launch of a Generic Version of Pyridostigmine Bromide Syrup

We are proud to announce that Milla Pharmaceuticals Inc., an A.forall company, in partnership with Acella Pharmaceuticals LLC, has successfully commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL. Pyridostigmine Bromide Syrup is indicated for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and rapid fatigue. A.forall CEO Filip Van de Vliet emphasized the significance of this achievement, stating, “After our rebranding into A.forall, uniting our teams and businesses under one single name that embodies our joint mission of...

Read More
Milla Pharmaceuticals Inc. a subsidiary of Alter Pharma Group is Becoming A.forall

Milla Pharmaceuticals Inc. a subsidiary of Alter Pharma Group is Becoming A.forall

The Alter Pharma Group is excited to announce its rebranding, uniting all its brands and businesses. We were already sharing One Mission, and now we also share one brand, one name: A.forall. This change represents an important milestone in A.forall’s pursuit of a world where patients can access high-quality, safe and innovative medicines at an affordable price and strengthens A.forall’s commitment to #MakingAffordableMedicinesAvailableToAll, offering new synergies and ways to leverage the skills and capacities of its 144 employees around the world. “A.forall” is more than a name: it’s a promise – for Accessibility, for Assurance, and for All – a pledge to make healthcare...

Read More
Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of Generic Version of Magnesium Sulfate in Water for Injection

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of Generic Version of Magnesium Sulfate in Water for Injection

Milla Pharmaceuticals successfully partnered with Athenex Pharmaceutical Division (APD) to release a generic version of Magnesium Sulfate in Water for Injection. The U.S. Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) for Magnesium Sulfate Injection, which is currently on the ASHP Drug Shortages List . The product is intended to prevent and control seizures in preeclampsia and eclampsia, and the launch aims to address recent supply issues for the medication in the U.S. market.  Erik Lazarich, President of the US Operations of the Alter Pharma Group and Director of Milla Pharmaceuticals, said, “By launching our...

Read More